Literature DB >> 8749852

Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling.

W Schiweck1, A Skerra.   

Abstract

The synthetic antibody model "M41" was rationally designed with a binding site complementary to chicken egg white cystatin as the prescribed antigen. In order to permit comparison between the computer model and an experimental three-dimensional structure of the artificial protein, its X-ray crystallographic analysis was pursued. For this purpose, M41 was expressed as a recombinant Fab fragment in E. coli by medium cell density fermentation employing the tightly regulated tetracycline promoter. The Fab fragment was efficiently purified via a His-6 tail fused to its heavy chain and immobilized metal affinity chromatography. To raise the chances for the productive formation of crystal packing contacts, three versions of the Fab fragment were generated with differing constant domains. One of these, the variant with murine C kappa and CH1 gamma 1 domains, was successfully crystallized by microseeding in a sitting drop. The orthorhombic crystals exhibited symmetry of the space group P2(1)2(1)2(1) with unit cell dimensions a = 104.7 A, b = 113.9 A, c = 98.8 A and diffracted X-rays to a nominal resolution of 2.5 A.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8749852     DOI: 10.1002/prot.340230411

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  10 in total

1.  Solubility engineering and crystallization of human apolipoprotein D.

Authors:  Amber Nasreen; Martin Vogt; Hyun Jin Kim; Andreas Eichinger; Arne Skerra
Journal:  Protein Sci       Date:  2005-12-01       Impact factor: 6.725

2.  Structural analysis of free and liganded forms of the Fab fragment of a high-affinity anti-cocaine antibody, h2E2.

Authors:  Kemin Tan; Min Zhou; Angela J Ahrendt; Norma E C Duke; Nassif Tabaja; William J Ball; Terence L Kirley; Andrew B Norman; Andrzej Joachimiak; Marianne Schiffer; Rosemarie Wilton; P Raj Pokkuluri
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2019-11-05       Impact factor: 1.056

3.  Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment.

Authors:  C Brösamle; A B Huber; M Fiedler; A Skerra; M E Schwab
Journal:  J Neurosci       Date:  2000-11-01       Impact factor: 6.167

4.  Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.

Authors:  Petra Kornberger; Arne Skerra
Journal:  MAbs       Date:  2013-12-09       Impact factor: 5.857

5.  Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.

Authors:  Daniel Harari; Nadine Kuhn; Renne Abramovich; Keren Sasson; Alla L Zozulya; Paul Smith; Martin Schlapschy; Rina Aharoni; Mario Köster; Raya Eilam; Arne Skerra; Gideon Schreiber
Journal:  J Biol Chem       Date:  2014-09-05       Impact factor: 5.157

6.  Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold.

Authors:  Magali Nicaise; Marielle Valerio-Lepiniec; Philippe Minard; Michel Desmadril
Journal:  Protein Sci       Date:  2004-05-28       Impact factor: 6.725

7.  High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.

Authors:  Claudia T Mendler; Lars Friedrich; Iina Laitinen; Martin Schlapschy; Markus Schwaiger; Hans-Jürgen Wester; Arne Skerra
Journal:  MAbs       Date:  2015       Impact factor: 5.857

8.  Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo.

Authors:  Emanuel Peplau; Francesco De Rose; Andreas Eichinger; Sybille Reder; Markus Mittelhäuser; Giorgia Scafetta; Markus Schwaiger; Wolfgang A Weber; Armando Bartolazzi; Calogero D'Alessandria; Arne Skerra
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

9.  PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins.

Authors:  Martin Schlapschy; Uli Binder; Claudia Börger; Ina Theobald; Klaus Wachinger; Sigrid Kisling; Dirk Haller; Arne Skerra
Journal:  Protein Eng Des Sel       Date:  2013-06-10       Impact factor: 1.650

10.  Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization.

Authors:  Zora Novakova; Nikola Belousova; Catherine A Foss; Barbora Havlinova; Marketa Gresova; Gargi Das; Ala Lisok; Adam Prada; Marketa Barinkova; Martin Hubalek; Martin G Pomper; Cyril Barinka
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.